Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
HU

NASDAQ · HUGE

FSD Pharma Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$0.09

Down-$0.01 (-10.10%)

Updated Aug 15, 2026, 4:01 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
66.67K
P/E ratio
-0.19
Dividend yield
0.00%
52-week range
— – —
Volume
22.02M
Avg. volume
188.74K

Price performance

HUGE price history

1M range · 0 trading sessions · Daily adjusted prices

HUGE does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest HUGE news

The latest Smart Investors Daily articles mentioning HUGE.

Stock researchCompany · Overview

HUGE research

Overview

Company profile and research snapshot.

Company profile

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.83
Implied upside
—
Analysts
7
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Sep 22, 2023

InvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin Harrington

VANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biotechnology company building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, continues with the development of its exciting new rapid detox drink UNBUZZD™.

GlobeNewswire Inc. · Aug 3, 2023

InvestmentPitch Media Video Features FSD Pharma’s Definitive Agreement Granting Exclusive Rights for Launch of UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink

VANCOUVER, British Columbia, Aug. 03, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is today’s feature company by InvestmentPitch Media.

Benzinga · Apr 13, 2023

EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics

The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space. Several esteemed professionals in the space talked about ways to get exposure Thursday (April 13) at Benzinga's Psychedelics Capital Conference in Miami Beach. Psyched For Psychedelics: The global psychedelics drugs space is expected to grow at a 13.3% CAGR through 2029. The market is still in its infancy, but with promising potential to help various mental health issues, long-term investors could be handsomely rewarded.  Maria Velkova, managing partner of Tabula Rasa Ventures, takes a holistic approach to investing in psychedelics. She reminded the crowd that drug development requires the collection of clinical data and the development of infrastructure, which takes time, but there is a well-defined path to market, she said. One of her favorite investments in the space is psychedelics insurance company Enthea.  "It's a really incredible company and a really key company in the space because one of the biggest hurdles we are going to face is ...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By